IP Library Granted Patent US 7,745,662
Granted Patent B2
US 7,745,662 · App. 12/465,995 · Granted Jun 29, 2010

Polycationic compounds and uses thereof

Assignee: Polymedix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,662
App. No.
12/465,995
Granted
Jun 29, 2010
Kind
B2
Abstract

Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.

Claims (9)

1. A compound of the formula:

2. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

3. The composition of claim 2 which is in the form of a capsule, cachet, tablet or lozenge.

4. The composition of claim 2 which is in the form of a powder or granule.

5. The composition of claim 2 which is in the form of a suspension or solution in an aqueous liquid or non-aqueous liquid.

6. A method of antagonizing heparin in a mammal comprising administering the compound of claim 1 to said mammal.

7. A method of antagonizing heparin in a mammal comprising administering the composition of claim 2 to said mammal.

8. A method of inhibiting Factor Xa in a mammal comprising administering the compound of claim 1 to said mammal.

9. A method of inhibiting Factor Xa in a mammal comprising administering the composition of claim 2 to said mammal.

Assignments (4)
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded Nov 27, 2013
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 031737/0550 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 17, 2013
From: POLYMEDIX, INC.; POLYMEDIX PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 029660/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2011
From: MOUSA, SHAKER; LIU, DAHUI
To: POLYMEDIX, INC.
Reel/Frame 025813/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: SHAKER, MOUSA
To: POLYMEDIX, INC.
Reel/Frame 024104/0204 →
Continuity (3)
Continuation 1115496200 · Jun 15, 2005
Provisional Application 6057928200 · Jun 15, 2004
Related Publication 20090239811A1 · Sep 24, 2009